Opthea Limited has discontinued the development of sozinibercept for the treatment of neovascular age-related macular degeneration (nAMD) following the failure of its phase 3 trials to meet primary endpoints. The drug, an Fc-fusion protein designed to inhibit VEGF-C and VEGF-D after intravitreal injection, did not show statistically significant improvements in vision compared to standard nAMD treatments. The company's solvency is now a concern.

Source: Retinal Physician